Literature DB >> 33531478

The promise of mRNA vaccines: a biotech and industrial perspective.

Nicholas A C Jackson1, Kent E Kester2, Danilo Casimiro2, Sanjay Gurunathan2, Frank DeRosa3.   

Abstract

mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response and multiple disease target manufacturing. A greater understanding of quality attributes that dictate translation efficiency, as well as a comprehensive appreciation of the importance of mRNA delivery, are influencing a new era of investment in development activities. The application of translational sciences and growing early-phase clinical experience continue to inform candidate vaccine selection. Here we review the state of the art for the prevention of infectious diseases by using mRNA and pertinent topics to the biotechnology and pharmaceutical industries.

Year:  2020        PMID： 33531478     DOI： 10.1038/s41541-020-0159-8

Source DB:  PubMed          Journal:  NPJ Vaccines        ISSN： 2059-0105            Impact factor:   7.344


  35 in total

1.  Promoter specificity determinants of T7 RNA polymerase.

Authors:  M Rong; B He; W T McAllister; R K Durbin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

2.  A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.

Authors:  Nurgun Kose; Julie M Fox; Gopal Sapparapu; Robin Bombardi; Rashika N Tennekoon; A Dharshan de Silva; Sayda M Elbashir; Matthew A Theisen; Elisabeth Humphris-Narayanan; Giuseppe Ciaramella; Sunny Himansu; Michael S Diamond; James E Crowe
Journal:  Sci Immunol       Date:  2019-05-17

3.  Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen.

Authors:  W F Cheng; C H Hung; C Y Chai; K F Hsu; L He; M Ling; T C Wu
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Inhomogeneity during deflation of excised canine lungs. II. Alveolar volumes.

Authors:  D O Warner; R E Hyatt; K Rehder
Journal:  J Appl Physiol (1985)       Date:  1988-10

5.  Free amino acids in the brain of patients with Parkinson's disease.

Authors:  J O Rinne; T Halonen; P J Riekkinen; U K Rinne
Journal:  Neurosci Lett       Date:  1988-11-22       Impact factor: 3.046

6.  Self-esteem and social-personal orientation of Indian 12- and 18-year-olds.

Authors:  M S Smart; R C Smart
Journal:  Psychol Rep       Date:  1970-08

7.  Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG.

Authors:  J Stepinski; C Waddell; R Stolarski; E Darzynkiewicz; R E Rhoads
Journal:  RNA       Date:  2001-10       Impact factor: 4.942

8.  [Restoration of depressed immune responses by PSK in C3H/He mice bearing the syngeneic X5563 tumor].

Authors:  K Matsunaga; I Morita; Y Oguchi; T Fujii; C Yoshikumi; K Nomoto
Journal:  Gan To Kagaku Ryoho       Date:  1986-12

9.  Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.

Authors:  Shinu John; Olga Yuzhakov; Angela Woods; Jessica Deterling; Kimberly Hassett; Christine A Shaw; Giuseppe Ciaramella
Journal:  Vaccine       Date:  2018-02-15       Impact factor: 3.641

10.  Immunoregulatory circuits among T-cell sets. I. T-helper cells induce other T-cell sets to exert feedback inhibition.

Authors:  D D Eardley; J Hugenberger; L McVay-Boudreau; F W Shen; R K Gershon; H Cantor
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307
View more
  1 in total

Review 1.  Self-amplifying RNA vaccines for infectious diseases.

Authors:  Kristie Bloom; Fiona van den Berg; Patrick Arbuthnot
Journal:  Gene Ther       Date:  2020-10-22       Impact factor: 5.250
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.